17 Jun 2021

GrandPa pain relief products (powder and tablets) remain suspended from registration and therefore not allowed in Botswana.

A media release from Botswana Medicines Regulatory Authority (BOMRA), says suspension follows a decision by the Market Authorisation Holder GlaxoSmithKline CH South Africa to temporarily halt supply of the products.

The release states that the Medicines and Related Substances Act, 2013, Section 23, prohibits importation, distribution, sale, storage and advertising of unregistered medical products.

It also says any person found guilty of breaching Section 23 may be liable to a fine of up to P100 000 and or imprisonment for a period not exceeding 10 years.

“BOMRA will continue working with key partners to make sure that effective measures are taken to prevent the illegal sale of these products that is largely carried out by some street vendors,” the release states.

It further says the public is  advised not to buy or consume unregistered medical products including GrandPa products because of safety concerns, instead, are advised to consult their doctor or pharmacist for alternative medicines available.

The release says the public should regard any GrandPa products circulating in the country to be unregistered, counterfeit, substandard or falsified and therefore may not be safe for human consumption. ends